Anúncio
Anúncio
SPRO
Spero Therapeutics, Inc. Common Stock
2.35
USDPatrocinado
+0.02
+0.69%
02 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
2.38
+0.03
+1.24%
Relatórios de Lucros SPRO
Rácio de surpresa positiva
SPRO separação 21 de 33 últimas estimativas.
64%
Próximo Relatório
Data do Próximo Relatório
25 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.20
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-100.00%
/+53.85%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-100.00%
/-47.37%
Spero Therapeutics, Inc. Common Stock earnings per share and revenue
On 13 de nov. de 2025, SPRO reported earnings of -0.13 USD per share (EPS) for Q3 25, beating the estimate of -0.25 USD, resulting in a 49.02% surprise. Revenue reached 5.44 milhão, compared to an expected --, with a 0.00% difference. The market reacted with a -1.23% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analistas forecast an EPS of -0.20 USD, with revenue projected to reach -- USD, implying an aumentar of 53.85% EPS, and diminuir of -100.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Spero Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Spero Therapeutics, Inc. Common Stock reported EPS of -$0.13, beating estimates by 49.02%, and revenue of $5.44M, 0% as expectations.
How did the market react to Spero Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -1.23%, changed from $2.44 before the earnings release to $2.41 the day after.
When is Spero Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 25 de mar. de 2026.
What are the forecasts for Spero Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analistas, Spero Therapeutics, Inc. Common Stock is expected to report EPS of -$0.20 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio